Drug Shortage Report for MAGNESIUM SULFATE INJECTION, USP
| Report ID | 217935 |
| Drug Identification Number | 02139499 |
| Brand name | MAGNESIUM SULFATE INJECTION, USP |
| Common or Proper name | MAGNESIUM SULFATE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | MAGNESIUM SULFATE |
| Strength(s) | 500MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 50 ML |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-02-02 |
| Actual start date | 2024-02-02 |
| Estimated end date | 2024-04-30 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2024-02-03 |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Magnesium Sulfate Injection, USP 500 mg/mL PBP Vial 50 mL effective February 5, 2024, until April 30, 2024. During this time, our Magnesium Sulfate Injection, USP 500 mg/mL SD Vial 10 mL is available for substitution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2024-02-03 | English | Compare |
| v2 | 2024-01-31 | French | Compare |
| v1 | 2024-01-31 | English | Compare |
Showing 1 to 3 of 3